Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain

Damla Damar Çelik; Berna Özbek Çelik

doi:10.12991/jrespharm.1945479

Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain

Abstract

Klebsiella pneumoniae is a critical pathogen frequently encountered in healthcare environments and is associated with a range of severe infections, including urinary tract infections, septicemia, meningitis, pneumonia, and surgical site infections. Furthermore, this bacterium can impact healthy, young individuals globally, rendering it a significant public health concern. Bacteriophages, viruses that specifically infect bacteria, present a promising alternative for the treatment of bacterial infections. The synergy between bacteriophages and antibiotics represents an effective therapeutic strategy, as it enhances antimicrobial efficacy and diminishes the likelihood of resistance development. This study assessed the in vitro activity of antibiotics, both independently and in conjunction with an isolated, specific bacteriophage, against a clinical strain of K. pneumoniae. A clinical K. pneumoniae strain was employed to isolate lytic bacteriophages. The lytic bacteriophage Kp14, isolated from lake water, produced clear plaques. The effects of combined treatments involving four antibiotics (ciprofloxacin, amikacin, meropenem, and ceftazidime) and the isolated bacteriophage were evaluated utilizing the Time–Kill Curve method. Synergistic activity was observed for ciprofloxacin and ceftazidime at both 1×MIC and 4×MIC, whereas synergism was observed for meropenem and amikacin at 4×MIC. Our findings demonstrate that bacteriophage therapy, when used in conjunction with conventional antibiotics, may serve as an effective alternative treatment for K. pneumoniae infections.

Keywords

References

[1] Galdiero E, Salvatore MM, Maione A, Carraturo F, Galdiero S, Falanga A, Andolfi A, Salvatore F, Guida, M. Impact of the peptide WMR-K on dual-Species biofilm Candida albicans/Klebsiella pneumoniae and on the untargeted metabolomic profile. Pathogens. 2021;10(2):214. https://doi.org/10.3390/pathogens10020214
[2] De Oliveira DM, Forde BM, Kidd TJ, Harris PN, Schembri MA, Beatson SA, Paterson DL, Walker MJ. Antimicrobial resistance in ESKAPE pathogens. Clin Microbiol Rev. 2020;33(3):10-1128. https://doi.org/10.1128/cmr.00181-19
[3] Saha U, Gondi R, Patil A, Saroj SD. CRISPR in modulating antibiotic resistance of ESKAPE pathogens. Mol Biotechnol. 2023;65(1):1-16. https://doi.org/10.1007/s12033-022-00543-8
[4] Wang S, Fan W, Jin R, Lan W, Zhao Y, Sun X. Bactericidal synergism between phage and antibiotics: A combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo. Eur J Pharm Biopharm. 2025;114759. https://doi.org/10.1016/j.ejpb.2025.114759
[5] European Centre for Disease Prevention and Control Antimicrobial resistance in the EU/EEA (EARS-net) AER for 2021, Stockholm. https://atlas.ecdc.europa.eu/ (accessed on 2026)
[6] Logan LK, Nguyen DC, Huang FAS, Qureshi NK, Charnot-Katsikas A, Bartlett AH et al. A multi-centered case-case-control study of factors associated with Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae infections in children and young adults. Pediatr Infect Dis. 2019;38(5):490-495. https://doi.org/10.1097/INF.0000000000002176
[7] Han ML, Nang SC, Lin YW, ZhuY, Yu HH, Wickremasinghe H, Barlow CK, Creek DJ, Crawford S, Rao G, Dai C, Barr JJ, Chan K, Schoooley RT, Velkov Li, J. Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination. Comput Struct Biotechnol. J. 2022;20:485-495. https://doi.org/10.1016/j.csbj.2021.12.039
[8] Ventola CL. The antibiotic resistance crisis, part 2: management strategies and new agents. PT. 2015;40:344–352.

[9] Pirnay JP, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Merabishvili, M. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 2024;9(6):1434-1453. https://doi.org/10.1038/s41564-024-01705-x
[10] Keen EC. Phage Therapy: Concept to Cure. Front Microbiol. 2012;3:238. https://doi.org/10.3389/fmicb.2012.00238
[11] Yang Q, Le S, Zhu T, Wu N. Regulations of phage therapy across the world. Front Microbiol. 2023;14:1250848. https://doi.org/10.3389/fmicb.2023.1250848
[12] Miller IP, Laney AG, Zahn G, Sheehan BJ, Whitley KV, Kuddus, R. H. Isolation and preliminary characterization of a novel bacteriophage vB_KquU_φKuK6 that infects the multidrug-resistant pathogen Klebsiella quasipneumoniae. Front Microbiol. 2024;15:1472729. https://doi.org/10.3389/fmicb.2024.1472729
[13] Gorodnichev RB, Krivulia AO, Kornienko MA, Abdraimova NK, Malakhova MV, Zaychikova MV et al. Phage-antibiotic combinations against Klebsiella pneumoniae: Impact of methodological approaches on effect evaluation. Front Microbiol. 2025;16:1530819. https://doi.org/10.3389/fmicb.2025.1530819
[14] Gu Liu C, Green SI, Min L, Clark JR, Salazar KC, Terwilliger AL, Kaplan HB, Trautner BW, Ramig RF, Maresso, AW. Phage-antibiotic synergy is driven by a unique combination of antibacterial mechanism of action and stoichiometry. mBio. 2020;11. https://doi.org/10.1128/mBio.01462-20 e01462-20.
[15] Li L, Gao X, Li M, Liu Y, Ma J, Wang, X et al. Relationship between biofilm formation and antibiotic resistance of Klebsiella pneumoniae and updates on antibiofilm therapeutic strategies. Front Cell Infect Microbiol. 2024;14:1324895 https://doi.org/ 10.3389/fcimb.2024.1324895
[16] Ramirez-Sanchez C, Gonzales F, Buckley M, Biswas B, Henry M, Deschenes MV, Aslam S. Successful treatment of Staphylococcus aureus prosthetic joint infection with bacteriophage therapy. Viruses. 2021;13(6):1182. https://doi.org/10.3390/v13061182
[17] Cano EJ, Caflisch KM, Bollyky PL, Van Belleghem JD, Patel R, Fackler J, Brownstein MJ, Horne B, Biswas B, Henry M, Malagon F, Lewallen DG, Suh GA. Phage therapy for limb-threatening prosthetic knee Klebsiella pneumoniae infection: case report and in vitro characterization of anti-biofilm activity. Clin Infect Dis. 2021;73(1):e144-e151. https://doi.org/10.1093/cid/ciaa705.
[18] Maddocks S, Fabijan AP, Ho J, Lin RC, Ben Zakour NL, Dugan C et al. Bacteriophage therapy of ventilator-associated pneumonia and empyema caused by Pseudomonas aeruginosa. Am J Respir Crit Care Med. 2019;200(9):1179-1181. https://doi.org/10.1164/rccm.201904-0839LE.
[19] Manohar P, Tamhankar AJ, Lundborg CS, Nachimuthu R. Therapeutic characterization and efficacy of bacteriophage cocktails infecting Escherichia coli, Klebsiella pneumoniae, and Enterobacter species. Front Microbiol. 2019;10:574. https://doi.org/10.3389/fmicb.2019.00574.
[20] Celik DD, Karaynir A, Dogan HS, Bozdogan B, Celik BO. Characterization and genomic analysis of PA-56 Pseudomonas phage from Istanbul, Turkey: Antibacterial and antibiofilm efficacy alone and with antibiotics. Heliyon. 2024;10(17). https://doi.org/10.1016/j.heliyon.2024.e36243
[21] Göller PC, Elsener T, Lorge D, Radulovic N, Bernardi V, Naumann A, Amri N, Khatchatourova E, Coutinho FH, Loessner MJ, Go´mez-Sanz E. Multi-species host range of staphylococcal phages isolated from wastewater. Nat Commun. 2021;12:6965. https://doi.org/10. 1038/s41467-021-27037-6
[22] Abedon, Bacteriophage ecology: population growth, evolution, and impact of bacterial viruses. In: Stephen T. (Ed.). Cambridge University Press, 2008.
[23] Şener G, Sakarcan A, Yeğen B. Melatonin as a radioprotective agent. In: Montilla P, Túnez I. (Eds). Melatonin: Present and Future. Nova Science Publishers, Inc., New York, 2008, pp.127-142.
[24] Pires DP, Oliveira H, Melo LDR, Sillankorva S, Azeredo J. Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl Microbiol Biotechnol. 2016;100:21412151. https://doi.org/10.1007/s00253-015-7247-0. 24
[25] Latka A, Leiman PG, Drulis-Kawa Z, Briers Y. Modeling the architecture of depolymerase-containing receptor binding proteins in Klebsiella phages. Front Microbiol. 2019;10:2649. https://doi.org/10.3389/ fmicb.2019.02649.
[26] Beamud B, García-González N, Gómez-Ortega M, González-Candelas F, Domingo-Calap P, Sanjuan R. Genetic determinants of host tropism in Klebsiella phages. Cell Rep. 2023;42(2). https://doi.org/10.1016/j.celrep.2023.112048
[27] Chen H, Liu H, Gong Y, Dunstan RA, Ma Z, Zhou C, Zhao D, Tang M, Lithgow T, Zhou T. A Klebsiella -phage cocktail to broaden the host range and delay bacteriophage resistance both in vitro and in vivo. Biofilms Microbiomes. 2024;10(1):127. https://doi.org/10.1038/s41522-024-00603-8
[28] Ferriol-González C, Domingo-Calap P. The host range of generalist and specialist phages in capsule-diverse Klebsiella hosts is driven by the evolvability of receptor-binding proteins. Plos Biol. 2025;23(11):e3003515. https://doi.org/10.1371/journal.pbio.3003515
[29] Dhillon S. Meropenem/vaborbactam: a review in complicated urinary tract infections. Drugs. 2018;78:1259. https://doi.org/10.1007/s40265- 018-0966-7
[30] Paranos P, Siopi M, Papanikolaou E, Vourli S, Kolia P, Pournaras S, Meletiadis J. Reversal of phenotypic resistance in multi-drug resistant carbapenemase-producing K. pneumoniae clinical isolates due to in vitro synergistic interactions between bacteriophages and antibiotics at clinically achievable concentrations. J Antimicrob Chemother. 2025;80(7):1997-2006. https://doi.org/10.1093/jac/dkaf163
[31] Eskenazi A, Lood C, Wubbolts J, Hites M, Balarjishvili, N., Leshkasheli, L., Lia Askilashvili K, Kvachadze L, van Noort V, Wagemans J, Jayankura M, Chanishvili N, Boer M, Nibbering P, Kutateladze M, Lavigne R, Merabishvili M, Pirnay JP. Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nat Commun. 2022;13:302. https://doi.org/10.1038/s41467-021-27656-z
[32] Shein AMS, Wannigama DL, Hurst C, Monk PN, Amarasiri M, Wongsurawat T, Abe S. Phage cocktail amikacin combination as a potential therapy for bacteremia associated with carbapenemase producing colistin resistant Klebsiella pneumoniae. Sci Rep. 2024;14(1):28992. https://doi.org/10.1038/s41598-024-79924-9
[33] Kim B, Kim S, Choi YJ, Shin M, Kim J. Evaluation of Bacteriophage and Antibiotic Synergy Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates. J Bacteriol Virol. 2025;55(2). https://doi.org/10.4167/jbv.2025.55.2.131
[34] Karaynir A, Salih H, Bozdoğan B, Güçlü Ö, Keskin D. Isolation and characterization of Brochothrix phage ADU4. Virus Res. 2022;321:198902. https://doi.org/10.1016/j.virusres.2022.198902
[35] CLSI (The Clinical & Laboratory Standards Institute), Performance Standards for Antimicrobial Susceptibility Testing, 32nd ed., Clinical and Laboratory Standards Institute, 2023. CLSI supplement M100.
[36] NCCLS (National Committee for Clinical Laboratory Standards), Performance Standard for Antimicrobial Disc Susceptibility Tests. Approved Standard, National Committee for Clinical Laboratory Standards, Villanova, 1999. P.A. Publication M2-A5. USA.

Details

Primary Language

English

Subjects

Pharmaceutical Microbiology

Journal Section

Research Article

Authors

Damla Damar Çelik ^*
0000-0001-9372-3168
Türkiye

Berna Özbek Çelik
0000-0001-8909-8398
Türkiye

Publication Date

October 6, 2026

Submission Date

May 23, 2026

Acceptance Date

September 29, 2026

Published in Issue

Year 2026 Volume: 30 Number: 5

DOI

https://doi.org/10.12991/jrespharm.1945479

IZ

https://izlik.org/JA57TG74KT

Cite

RIS / Bibtex

APA

Damar Çelik, D., & Özbek Çelik, B. (2026). Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain. Journal of Research in Pharmacy, 30(5), 1331-1340. https://doi.org/10.12991/jrespharm.1945479

AMA

1.Damar Çelik D, Özbek Çelik B. Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain. J. Res. Pharm. 2026;30(5):1331-1340. doi:10.12991/jrespharm.1945479

Chicago

Damar Çelik, Damla, and Berna Özbek Çelik. 2026. “Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics Against Klebsiella Pneumoniae Strain”. Journal of Research in Pharmacy 30 (5): 1331-40. https://doi.org/10.12991/jrespharm.1945479.

EndNote

Damar Çelik D, Özbek Çelik B (October 1, 2026) Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain. Journal of Research in Pharmacy 30 5 1331–1340.

IEEE

[1]D. Damar Çelik and B. Özbek Çelik, “Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain”, J. Res. Pharm., vol. 30, no. 5, pp. 1331–1340, Oct. 2026, doi: 10.12991/jrespharm.1945479.

ISNAD

Damar Çelik, Damla - Özbek Çelik, Berna. “Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics Against Klebsiella Pneumoniae Strain”. Journal of Research in Pharmacy 30/5 (October 1, 2026): 1331-1340. https://doi.org/10.12991/jrespharm.1945479.

JAMA

1.Damar Çelik D, Özbek Çelik B. Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain. J. Res. Pharm. 2026;30:1331–1340.

MLA

Damar Çelik, Damla, and Berna Özbek Çelik. “Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics Against Klebsiella Pneumoniae Strain”. Journal of Research in Pharmacy, vol. 30, no. 5, Oct. 2026, pp. 1331-40, doi:10.12991/jrespharm.1945479.

Vancouver

1.Damla Damar Çelik, Berna Özbek Çelik. Isolation of Bacteriophage Kp14 and Its Combination of Various Antibiotics against Klebsiella pneumoniae Strain. J. Res. Pharm. 2026 Oct. 1;30(5):1331-40. doi:10.12991/jrespharm.1945479